Novel Agents in Breast Cancer and Monoclonal Antibodies

July 15, 2015
Howard A. “Skip” Burris, III, MD

Howard A. “Skip” Burris, III, MD, president, Clinical Operations, chief medical officer and executive director, Drug Development Program, Sarah Cannon, discusses the novel agents in breast cancer and monoclonal antibodies.

Burris mentions the many new classes of therapies discussed for breast cancer, as well as the focus on drugs that will target receptors on the cancer cells and potentially stimulate the immune system.

He also explains the positive results discovered from the treatment of margetuximab in patients.

Howard A. “Skip” Burris, III, MD, president, Clinical Operations, chief medical officer and executive director, Drug Development Program, Sarah Cannon, discusses the novel agents in breast cancer and monoclonal antibodies.